Published in J Cardiovasc Pharmacol Ther on March 01, 2011
Matrix-dependent perturbation of TGFβ signaling and disease. FEBS Lett (2012) 1.31
Role of TGF-β signaling in inherited and acquired myopathies. Skelet Muscle (2011) 1.28
Treatment of dystrophinopathic cardiomyopathy: review of the literature and personal results. Acta Myol (2012) 1.14
Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs (2012) 1.11
Angiotensin receptor blockade mediated amelioration of mucopolysaccharidosis type I cardiac and craniofacial pathology. J Inherit Metab Dis (2016) 1.10
Inhibiting TGF-β activity improves respiratory function in mdx mice. Am J Pathol (2011) 1.09
Novel approach to meta-analysis of microarray datasets reveals muscle remodeling-related drug targets and biomarkers in Duchenne muscular dystrophy. PLoS Comput Biol (2012) 1.02
Prednisolone attenuates improvement of cardiac and skeletal contractile function and histopathology by lisinopril and spironolactone in the mdx mouse model of Duchenne muscular dystrophy. PLoS One (2014) 1.01
Myocardial fibrosis burden predicts left ventricular ejection fraction and is associated with age and steroid treatment duration in duchenne muscular dystrophy. J Am Heart Assoc (2015) 1.00
Membrane sealant Poloxamer P188 protects against isoproterenol induced cardiomyopathy in dystrophin deficient mice. BMC Cardiovasc Disord (2011) 0.99
Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. PLoS One (2011) 0.96
Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects. J Pharmacol Exp Ther (2012) 0.90
Pharmacologic management of Duchenne muscular dystrophy: target identification and preclinical trials. ILAR J (2014) 0.88
Sarcolemma instability during mechanical activity in Largemyd cardiac myocytes with loss of dystroglycan extracellular matrix receptor function. Hum Mol Genet (2011) 0.86
Angiotensin II type 1 receptor antagonists alleviate muscle pathology in the mouse model for laminin-α2-deficient congenital muscular dystrophy (MDC1A). Skelet Muscle (2012) 0.86
Omigapil treatment decreases fibrosis and improves respiratory rate in dy(2J) mouse model of congenital muscular dystrophy. PLoS One (2013) 0.85
Low-dose atorvastatin, losartan, and particularly their combination, provide cardiovascular protection in isolated rat heart and aorta. Heart Vessels (2012) 0.85
Current and emerging treatment strategies for Duchenne muscular dystrophy. Neuropsychiatr Dis Treat (2016) 0.83
Vascular-targeted therapies for Duchenne muscular dystrophy. Skelet Muscle (2013) 0.80
Therapeutic strategies for preventing skeletal muscle fibrosis after injury. Front Pharmacol (2015) 0.80
Conditional expression of TGF-β1 in skeletal muscles causes endomysial fibrosis and myofibers atrophy. PLoS One (2013) 0.80
Targeting TGF-β Signaling by Antisense Oligonucleotide-mediated Knockdown of TGF-β Type I Receptor. Mol Ther Nucleic Acids (2014) 0.79
Evaluation of 11C-acetate and 18F-FDG PET/CT in mouse multidrug resistance gene-2 deficient mouse model of hepatocellular carcinoma. BMC Med Imaging (2015) 0.78
A randomized, double-blind trial of lisinopril and losartan for the treatment of cardiomyopathy in duchenne muscular dystrophy. PLoS Curr (2013) 0.78
Speckle tracking analysis of the left ventricular anterior wall shows significantly decreased relative radial strain patterns in dystrophin deficient mice after 9 months of age. PLoS Curr (2011) 0.77
Proteomic profiling of the dystrophin-deficient mdx phenocopy of dystrophinopathy-associated cardiomyopathy. Biomed Res Int (2014) 0.76
Biochemical and Functional Comparisons of mdx and Sgcg(-/-) Muscular Dystrophy Mouse Models. Biomed Res Int (2015) 0.75
The Effects of Experimental Sleep Apnea on Cardiac and Respiratory Functions in 6 and 18 Month Old Dystrophic (mdx) Mice. PLoS One (2016) 0.75
Angiotensin-dependent autonomic dysregulation precedes dilated cardiomyopathy in a mouse model of muscular dystrophy. Exp Physiol (2015) 0.75
Inhibition of inflammation with celastrol fails to improve muscle function in dysferlin-deficient A/J mice. J Neurol Sci (2015) 0.75
Magnetic Resonance Imaging Is Sensitive to Pathological Amelioration in a Model for Laminin-Deficient Congenital Muscular Dystrophy (MDC1A). PLoS One (2015) 0.75
High throughput screening in duchenne muscular dystrophy: from drug discovery to functional genomics. Biology (Basel) (2014) 0.75
PDGFRα signalling promotes fibrogenic responses in collagen-producing cells in Duchenne muscular dystrophy. J Pathol (2016) 0.75
CCR2 deficiency does not provide sustained improvement of muscular dystrophy in mdx5cv mice. FASEB J (2016) 0.75
Pharmacological therapeutics targeting the secondary defects and downstream pathology of Duchenne muscular dystrophy. Expert Opin Orphan Drugs (2016) 0.75
Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell (1987) 20.27
Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science (2006) 10.25
Non-Smad pathways in TGF-beta signaling. Cell Res (2009) 5.54
Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med (2007) 5.25
Contractile properties of skeletal muscles from young, adult and aged mice. J Physiol (1988) 4.97
Effect of perindopril on the onset and progression of left ventricular dysfunction in Duchenne muscular dystrophy. J Am Coll Cardiol (2005) 3.64
Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation (2001) 3.21
Genetic predictors and remodeling of dilated cardiomyopathy in muscular dystrophy. Circulation (2005) 2.58
Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscul Disord (2004) 2.34
Fibrosis in heart disease: understanding the role of transforming growth factor-beta in cardiomyopathy, valvular disease and arrhythmia. Immunology (2006) 2.26
Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve (2009) 2.19
Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies. Proc Natl Acad Sci U S A (2000) 2.13
Left ventricular function and response to enalapril in patients with duchenne muscular dystrophy during the second decade of life. Am J Cardiol (2006) 1.74
Perindopril preventive treatment on mortality in Duchenne muscular dystrophy: 10 years' follow-up. Am Heart J (2007) 1.69
Duchenne muscular dystrophy: prevalence and patterns of cardiac involvement. Indian J Pediatr (2005) 1.63
Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord (2008) 1.52
Emergent dilated cardiomyopathy caused by targeted repair of dystrophic skeletal muscle. Mol Ther (2008) 1.47
Progression of dystrophic features and activation of mitogen-activated protein kinases and calcineurin by physical exercise, in hearts of mdx mice. FEBS Lett (2002) 1.20
Contrasting effects of steroids and angiotensin-converting-enzyme inhibitors in a mouse model of dystrophin-deficient cardiomyopathy. Eur J Heart Fail (2009) 1.19
Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cell Physiol Biochem (2009) 1.14
Early manifestation of alteration in cardiac function in dystrophin deficient mdx mouse using 3D CMR tagging. J Cardiovasc Magn Reson (2009) 1.13
Role of interleukin-6 in cardiomyocyte/cardiac fibroblast interactions during myocyte hypertrophy and fibroblast proliferation. J Cell Physiol (2005) 1.08
Regulation of angiotensin II-stimulated osteopontin expression in cardiac microvascular endothelial cells: role of p42/44 mitogen-activated protein kinase and reactive oxygen species. J Cell Physiol (2001) 1.02
Modulation of disease severity in mice with targeted disruption of the acid alpha-glucosidase gene. Neuromuscul Disord (2000) 1.00
ERK1/2 and JNKs, but not p38 kinase, are involved in reactive oxygen species-mediated induction of osteopontin gene expression by angiotensin II and interleukin-1beta in adult rat cardiac fibroblasts. J Cell Physiol (2004) 0.99
AT2 receptor mediates the cardioprotective effects of AT1 receptor antagonist in post-myocardial infarction remodeling. Life Sci (2006) 0.98
Long-term therapy with deflazacort decreases myocardial fibrosis in mdx mice. Muscle Nerve (2009) 0.93
Evaluation of skeletal and cardiac muscle function after chronic administration of thymosin beta-4 in the dystrophin deficient mouse. PLoS One (2010) 0.90
Chronic effect of losartan in a murine model of dilated cardiomyopathy: comparison with captopril. J Pharmacol Exp Ther (1995) 0.82
N-acetylcysteine abolishes the protective effect of losartan against left ventricular remodeling in cardiomyopathy hamster. Antioxid Redox Signal (2008) 0.81
[Effects of fosinopril and losartan on the expression of Toll- like receptor 4 in renal tubular epithelia cells]. Zhong Nan Da Xue Xue Bao Yi Xue Ban (2008) 0.79
[Blockade of renin-angiotensin system attenuates cardiac remodeling in rats undergoing aortic stenosis]. Arq Bras Cardiol (2005) 0.78
Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature (2005) 23.04
Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01
Glucose restriction inhibits skeletal myoblast differentiation by activating SIRT1 through AMPK-mediated regulation of Nampt. Dev Cell (2008) 5.51
Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol (2007) 5.16
The transcription factor PU.1 is required for the development of IL-9-producing T cells and allergic inflammation. Nat Immunol (2010) 3.97
Genomics, intellectual disability, and autism. N Engl J Med (2012) 3.74
Suppression of IL7Ralpha transcription by IL-7 and other prosurvival cytokines: a novel mechanism for maximizing IL-7-dependent T cell survival. Immunity (2004) 3.67
Elevated stearoyl-CoA desaturase-1 expression in skeletal muscle contributes to abnormal fatty acid partitioning in obese humans. Cell Metab (2005) 3.47
Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet (2006) 2.86
Enhanced autoantigen expression in regenerating muscle cells in idiopathic inflammatory myopathy. J Exp Med (2005) 2.82
An interactive power analysis tool for microarray hypothesis testing and generation. Bioinformatics (2006) 2.62
Sources of variability and effect of experimental approach on expression profiling data interpretation. BMC Bioinformatics (2002) 2.31
Klf2 is an essential regulator of vascular hemodynamic forces in vivo. Dev Cell (2006) 2.26
Nuclear envelope dystrophies show a transcriptional fingerprint suggesting disruption of Rb-MyoD pathways in muscle regeneration. Brain (2006) 2.22
Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis (2008) 2.20
Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve (2009) 2.19
Changes in ubiquitin proteasome pathway gene expression in skeletal muscle with exercise and statins. Arterioscler Thromb Vasc Biol (2005) 2.12
Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest (2009) 2.10
Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci U S A (2008) 2.06
Gene profiling in spinal cord injury shows role of cell cycle in neuronal death. Ann Neurol (2003) 2.06
SLC30A8 nonsynonymous variant is associated with recovery following exercise and skeletal muscle size and strength. Diabetes (2013) 2.05
Signal transducer and activator of transcription 4 is required for the transcription factor T-bet to promote T helper 1 cell-fate determination. Immunity (2008) 2.04
Calorie-related rapid onset of alveolar loss, regeneration, and changes in mouse lung gene expression. Am J Physiol Lung Cell Mol Physiol (2003) 2.04
Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. J Proteome Res (2006) 2.04
Deacetylase inhibitors increase muscle cell size by promoting myoblast recruitment and fusion through induction of follistatin. Dev Cell (2004) 2.01
Interactively optimizing signal-to-noise ratios in expression profiling: project-specific algorithm selection and detection p-value weighting in Affymetrix microarrays. Bioinformatics (2004) 1.98
Variability in muscle size and strength gain after unilateral resistance training. Med Sci Sports Exerc (2005) 1.95
ACE ID genotype and the muscle strength and size response to unilateral resistance training. Med Sci Sports Exerc (2006) 1.86
Modulation of coreceptor transcription during positive selection dictates lineage fate independently of TCR/coreceptor specificity. Immunity (2005) 1.85
Loss of emerin at the nuclear envelope disrupts the Rb1/E2F and MyoD pathways during muscle regeneration. Hum Mol Genet (2006) 1.85
Gene expression profiling in DQA1*0501+ children with untreated dermatomyositis: a novel model of pathogenesis. J Immunol (2002) 1.83
Tissue-specific alternative splicing of TCF7L2. Hum Mol Genet (2009) 1.80
Histidyl-tRNA synthetase and asparaginyl-tRNA synthetase, autoantigens in myositis, activate chemokine receptors on T lymphocytes and immature dendritic cells. J Exp Med (2002) 1.78
The RNA helicases p68/p72 and the noncoding RNA SRA are coregulators of MyoD and skeletal muscle differentiation. Dev Cell (2006) 1.78
Constitutive activation of MAPK cascade in acute quadriplegic myopathy. Ann Neurol (2004) 1.77
GRB14, GPD1, and GDF8 as potential network collaborators in weight loss-induced improvements in insulin action in human skeletal muscle. Physiol Genomics (2006) 1.67
Apolipoprotein E polymorphisms and severity of cerebral palsy: a cross-sectional study in 255 children in Norway. Dev Med Child Neurol (2013) 1.66
Dysferlin deficiency enhances monocyte phagocytosis: a model for the inflammatory onset of limb-girdle muscular dystrophy 2B. Am J Pathol (2008) 1.65
Deconstructing Pompe disease by analyzing single muscle fibers: to see a world in a grain of sand... Autophagy (2007) 1.60
Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther (2005) 1.59
ACTN3 genotype is associated with increases in muscle strength in response to resistance training in women. J Appl Physiol (1985) (2005) 1.57
Embryonic myogenesis pathways in muscle regeneration. Dev Dyn (2004) 1.57
Differential dependency network analysis to identify condition-specific topological changes in biological networks. Bioinformatics (2008) 1.56
Microtubules underlie dysfunction in duchenne muscular dystrophy. Sci Signal (2012) 1.54
Probe set algorithms: is there a rational best bet? BMC Bioinformatics (2006) 1.53
Interleukin-7 enhances the Th1 response to promote the development of Sjögren's syndrome-like autoimmune exocrinopathy in mice. Arthritis Rheum (2013) 1.53
Analysis of a genomic island housing genes for DNA S-modification system in Streptomyces lividans 66 and its counterparts in other distantly related bacteria. Mol Microbiol (2007) 1.53
Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord (2008) 1.52
ACTN3 and MLCK genotype associations with exertional muscle damage. J Appl Physiol (1985) (2005) 1.52
Development of autoantibodies against muscle-specific FHL1 in severe inflammatory myopathies. J Clin Invest (2015) 1.51
Functional characteristics of dystrophic skeletal muscle: insights from animal models. J Appl Physiol (1985) (2002) 1.50
Slug is a novel downstream target of MyoD. Temporal profiling in muscle regeneration. J Biol Chem (2002) 1.50
Functional polymorphisms associated with human muscle size and strength. Med Sci Sports Exerc (2004) 1.49
Heterotaxy and complex structural heart defects in a mutant mouse model of primary ciliary dyskinesia. J Clin Invest (2007) 1.49
The cooperative international neuromuscular research group Duchenne natural history study--a longitudinal investigation in the era of glucocorticoid therapy: design of protocol and the methods used. Muscle Nerve (2013) 1.48
{N,N-Dimethyl-N'-[phen-yl(2-pyrid-yl)methyl-ene]ethane-1,2-diamine-κN,N',N''}dithio-cyanato-κN,κS-copper(II). Acta Crystallogr Sect E Struct Rep Online (2009) 1.44
Proteomics and systems biology in exercise and sport sciences research. Exerc Sport Sci Rev (2007) 1.43
Applications of targeted gene capture and next-generation sequencing technologies in studies of human deafness and other genetic disabilities. Hear Res (2012) 1.43
Contribution of epidermal stem cells to hypertrophic scars pathogenesis. Med Hypotheses (2009) 1.42
Inflammasome up-regulation and activation in dysferlin-deficient skeletal muscle. Am J Pathol (2010) 1.41
Pillars Article: Coreceptor Reversal in the Thymus: Signaled CD4+8+ Thymocytes Initially Terminate CD8 Transcription Even When Differentiating into CD8+ T Cells. Immunity. 2000. 13: 59-71. J Immunol (2016) 1.41
Patterns of global gene expression in rat skeletal muscle during unloading and low-intensity ambulatory activity. Physiol Genomics (2003) 1.41
The PEPR GeneChip data warehouse, and implementation of a dynamic time series query tool (SGQT) with graphical interface. Nucleic Acids Res (2004) 1.40
Distinct requirements for the naturally occurring splice forms Stat4alpha and Stat4beta in IL-12 responses. EMBO J (2003) 1.39
Rare missense and synonymous variants in UBE1 are associated with X-linked infantile spinal muscular atrophy. Am J Hum Genet (2008) 1.39
A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscul Disord (2002) 1.38
Suppression of autophagy permits successful enzyme replacement therapy in a lysosomal storage disorder--murine Pompe disease. Autophagy (2010) 1.38
Cardiovascular phenotyping of fetal mice by noninvasive high-frequency ultrasound facilitates recovery of ENU-induced mutations causing congenital cardiac and extracardiac defects. Physiol Genomics (2005) 1.35
Bodywide skipping of exons 45-55 in dystrophic mdx52 mice by systemic antisense delivery. Proc Natl Acad Sci U S A (2012) 1.32
Skipping toward personalized molecular medicine. N Engl J Med (2007) 1.30
Response of rat muscle to acute resistance exercise defined by transcriptional and translational profiling. J Physiol (2002) 1.29
Integrated DNA, cDNA, and protein studies in Becker muscular dystrophy show high exception to the reading frame rule. Hum Mutat (2008) 1.29
Canine models of Duchenne muscular dystrophy and their use in therapeutic strategies. Mamm Genome (2012) 1.28
Stem cell-delivery therapeutics for periodontal tissue regeneration. Biomaterials (2012) 1.27
Fgfr4 is required for effective muscle regeneration in vivo. Delineation of a MyoD-Tead2-Fgfr4 transcriptional pathway. J Biol Chem (2005) 1.27
One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice. Mol Ther (2010) 1.25
VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects. EMBO Mol Med (2013) 1.22
Novel CLCN1 mutations with unique clinical and electrophysiological consequences. Brain (2002) 1.22